NASDAQ · STOCK
Colgate-Palmolive
$92.27
52W $74.55 – $99.33
53/100
$72.83B
35.2
0.33
Price History (6M)
Executive Summary
7 analysts weighed in with 43% agreement on a neutral lean. Portfolio Manager: Portfolio position concentration is currently healthy. Growth Analyst: EPS declining -27.0% YoY despite any revenue growth. Overall recommendation: WATCH.
Bull & Bear Case
Bull Case
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- MACD histogram is negative (-0.064) — bearish momentum.
- Fundamental score is weak (33.3/100) — poor financial health or expensive valuation.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
53/100
Agreement
43%
Analysts
7
Conviction
Contested
Value Analyst
neutral
45
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 475.1% shows genuine earnings power backing the valuation
− P/E of 35.4 is moderate-to-rich
Growth Analyst
bearish
32
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -27.0% YoY despite any revenue growth
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 147.93) amplifies downside in a stress scenario
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
50.6
Neutral
MACD Histogram
-0.064
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$90.78
Resistance
$94.16
Bollinger %B
0.60
Inside Bands
Price vs Moving Averages
EMA 9
$92.51
Below
EMA 21
$91.59
Above
EMA 50
$89.99
Above
EMA 200
$87.47
Above
Fundamental Analysis
Valuation
10
Growth
35
Profitability
88
Financial Health
1
Valuation
P/E Ratio
35.2×
P/B Ratio
—
PEG Ratio
—
Dividend Yield
2.33%
52W High
$99.33
52W Low
$74.55
Quality & Growth
ROE
47513.0%
ROA
1229.0%
Gross Margin
6006.0%
Operating Margin
1542.0%
Revenue Growth YoY
+425.0%
Debt / Equity
—
AI Fundamental Assessment
P/E ratio of 35.2 (rich relative to a 15-40x range); Price-to-book of 1179.5x; Revenue growth (YoY) of 4.2%; EPS growth (YoY) of -27.0%; Return on equity of 475.1%; Return on assets of 12.3%; Net margin of 10.0%; Gross margin of 60.1%; Current ratio of 0.83 (tight short-term liquidity); Debt-to-equity of 147.93; Most recent quarter missed estimates by 0.3%; EPS growth decelerating (+4.4% -> +2.1% QoQ); Analyst estimates rising over recent quarters
Key Risks
- MACD histogram is negative (-0.064) — bearish momentum.
- Fundamental score is weak (33.3/100) — poor financial health or expensive valuation.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full CL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile